Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27349835 | 0.84 | OPRM1 (0.57) | GPR119OPRM1OPRD1OGFRL1STS | |
| SCHEMBL27351608 | 0.82 | CYP11B2 (0.36) | GPR119 | |
| SCHEMBL27349815 | 0.80 | GPR119 (0.49) | GPR119OPRM1OPRD1OGFRL1CYP3A4 | |
| SCHEMBL27349812 | 0.80 | GPR119 (0.51) | GPR119 | |
| SCHEMBL27349830 | 0.76 | STS (0.46) | GPR119STS | |
| SCHEMBL28510140 | 0.73 | HSD11B1 (0.50) | GPR119 | |
| SCHEMBL27349818 | 0.72 | OPRM1 (0.45) | GPR119OPRM1OPRD1OGFRL1STS | |
| SCHEMBL16135849 | 0.70 | GPR119 (0.46) | GPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL947135 | 0.70 | LMNA (0.62) | GPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL28812695 | 0.70 | GPR119 (0.54) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | GPR119 926/4885OPRM1 4336/4885OPRD1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.